Г





00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No:			Patient Phone:		6/13/2025 Physician Name: Specialty: Physician Office Telephone:				
		NPI#:							
Physician Office Address:									
Dru	ig Name (specify drug)			_					
	antity:		-						
		Expected Length of Therapy: ICD Code:							
Coi									
Ple	ase check the appropriat	te answer for each applica	able question.						
1.	What is the diagnosis?				_				
	Pediatric growth horm go to 2)	none (GH) deficiency (inclue	ding panhypopituitarism) (If checked,						
	Other, please specify.	. (If checked, no further que	estions)						
2.	Is the request for continut hormone product indicat	uation of therapy of the required for pediatric growth horr	uested drug, or another growth none (GH) deficiency?	Y		N			
3.	Is the patient currently reprint patient assistance progr		rough samples or a manufacturer's						
	Yes (If checked, go to	o 13)							
	No (If checked, go to	4)							
	Unknown (If checked,	, go to 13)							
4.	Has the patient been pre a health plan or pharma	eviously approved for prior a cy benefit manager?	authorization for growth hormone unde	er Y		Ν			
5.	(approximate duration is health plan/pharmacy be Prior authorization appro	s acceptable), B) Date of the enefit manager, D) Date of t	per: A) Total duration of treatment e last dose administered, C) Approving the prior authorization/approval, and E IRED: If Yes, attach medical records. entation	Y		Ν			
6.	Is information on the pat	tient's current age provided	? Indicate age in years and months.	Y		Ν			
7.	Is information on the pat	tient's current height provide	ed? Indicate height in centimeters.	Y		N			
8.	Is information on the dat	te growth hormone therapy	was initiated provided?	Y		N			
9.	Are the epiphyses still o	pen?							
	Yes, confirmed by X-r	ray (If checked, go to 10)							
	Yes, but X-ray not ava	ailable (If checked, go to 10)						

Γ				
	No (If checked, no further questions)			
10.	Is the patient growing at a rate of more than 2 cm/year? ACTION REQUIRED: If Yes, attach current growth chart showing growth velocity. ACTION REQUIRED: Submit supporting documentation	Y	N	
11.	Is there a clinical reason for the lack of efficacy?	Y	Ν	
12.	What is the clinical reason for the lack of efficacy?			
	On treatment less than 1 year - Indicate treatment duration (If checked, no further questions)			
	Nearing final adult height or in later stages of puberty (If checked, no further questions)			
	Other, please specify. (If checked, no further questions)			
13.	Is the patient 1 year of age or older?	Y	N	
14.	Was the patient diagnosed with growth hormone (GH) deficiency as a neonate?	Y	N	
15.	Is there documentation to support the diagnosis of neonatal growth hormone (GH) deficiency (such as hypoglycemia with random GH level, evidence of multiple pituitary hormone deficiencies, magnetic resonance imaging [MRI] results)? ACTION REQUIRED: If Yes, attach medical documentation, laboratory report, or imaging report. ACTION REQUIRED: Submit supporting documentation	Y	Ν	
16.	Is the documentation supporting the diagnosis of neonatal growth hormone (GH) deficiency (such as hypoglycemia with random GH level, evidence of multiple pituitary hormone deficiencies, magnetic resonance imaging [MRI] results) attached?	Y	N	
17.	Does the patient have 2 pretreatment pharmacologic provocative tests for growth hormone (GH)? ACTION REQUIRED: If Yes, attach laboratory report or medical record of pretreatment provocative test results. ACTION REQUIRED: Submit supporting documentation	Y	N	
18.	What is the peak level? Indicate in ng/ml.			
	Less than 10 ng/ml (If checked, go to 22)			
	Greater than or equal to 10 ng/ml (If checked, go to 19)			
19.	Does the patient have a pituitary or central nervous system (CNS) disorder?	Y	N	
20.	What is the pituitary or central nervous system (CNS) disorder?			
	Transcription factor defect (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2) (If checked, go to 21)			
	Growth hormone releasing hormone (GHRH) receptor gene defect (If checked, go to 21)			
	GH secretagogue receptor gene defect (If checked, go to 21)			
	GH gene defect (If checked, go to 21)			
	Optic nerve hypoplasia/septo-optic dysplasia (If checked, go to 21)			
	Agenesis of corpus callosum (If checked, go to 21)			
	Empty sella syndrome (If checked, go to 21)			
	Ectopic posterior pituitary (If checked, go to 21)			
	Pituitary aplasia/hypoplasia (If checked, go to 21)			
	Pituitary stalk defect (If checked, go to 21)			
	Holoprosencephaly (If checked, go to 21)			

	Encephalocele (If checked, go to 21)			
	Hydrocephalus (If checked, go to 21)			
	Anencephaly or prosencephaly (If checked, go to 21)			
	Arachnoid cyst (If checked, go to 21)			
	Other mid-line facial defects (e.g., single central incisor, cleft lip/palate) (If checked, go to 21)			
	Vascular malformation (If checked, go to 21)			
	CNS tumor/neoplasm (e.g., craniopharyngioma, glioma/astrocytoma, pituitary adenoma, germinoma) (If checked, go to 21)			
	Cyst (Rathke cleft cyst or arachnoid cleft cyst) (If checked, go to 21)			
	Surgery (If checked, go to 21)			
	Radiation (If checked, go to 21)			
	Chemotherapy (If checked, go to 21)			
	CNS infection (If checked, go to 21)			
	CNS infarction (If checked, go to 21)			
	Inflammatory process (e.g., autoimmune hypophysitis) (If checked, go to 21)			
	Infiltrative process (e.g., sarcoidosis, histiocytosis, hemochromatosis) (If checked, go to 21)			
	Head trauma/traumatic brain injury (If checked, go to 21)			
	Aneurysmal subarachnoid hemorrhage (If checked, go to 21)			
	Perinatal or postnatal trauma (If checked, go to 21)			
	Surgery of the pituitary or hypothalamus (If checked, go to 21)			
	Other, please specify. (If checked, no further questions)			
21.	Does the patient have a pretreatment insulin-like growth factor-1 (IGF-1) level greater than 2 standard deviations (SD) below the mean based on the laboratory reference range? ACTION REQUIRED: If Yes, attach laboratory report or medical record of pretreatment IGF-1 level. ACTION REQUIRED: Submit supporting documentation	Y	N	
22.	Is one pretreatment height and the patient's age at the time the height was recorded provided? Indicate height in centimeters and age in years and months.	Y	N	
23.	Is a second pretreatment height and the patient's age at the time the height was recorded provided? Indicate height in centimeters and age in years and months.	Y	N	
24.	What is the pretreatment age?			
	Less than 2.5 years of age (If checked, go to 25)			
	Greater than or equal to 2.5 years of age (If checked, go to 26)			
25.	Does the patient have a pretreatment height of greater than 2 standard deviations (SD) below the mean for age and gender AND a slow growth velocity? ACTION REQUIRED: If Yes, attach a growth chart showing pretreatment heights and growth velocity ACTION REQUIRED: Submit supporting documentation	Y	N	
26.	Does the patient have a pretreatment height of greater than 2 standard deviations (SD) below the mean for age and gender? ACTION REQUIRED: If Yes, attach a growth chart showing pretreatment height. ACTION REQUIRED: Submit supporting documentation	Y	N	
27.	Does the patient have a pretreatment 1-year height velocity of greater than 1 standard deviation (SD) below the mean for age and gender? ACTION REQUIRED: If Yes, attach a growth chart showing pretreatment height velocity. ACTION REQUIRED: Submit supporting documentation	Y	N	

Γ

28.	Does the patient have a pretreatment 1-year height velocity of greater than 2 standard deviations (SD) below the mean for age and gender? ACTION REQUIRED: If Yes, attach a growth chart showing pretreatment height velocity. ACTION REQUIRED: Submit supporting documentation	Y	N	
29.	Are the epiphyses still open?	Y	Ν	
30.	Are the laboratory reports or medical record documentation of the pretreatment provocative tests for growth hormone (GH), pretreatment insulin-like growth factor-1 (IGF-1) levels, and growth chart attached, if applicable?	Y	N	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.